Brian McKelligon is CEO & President at Akoya Biosciences, Inc. (AKYA). They have made 3 open-market trades across 1 company since 2022, most recently 2025-07-08.
CIK 0001857447
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKYA | 947,688 | $1.2M |
Shares reported on the most recent Form 4, priced at the 2025-07-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKYA | SELL · 10b5-1 | 2024-06-11 | 2024-06-12 | $2.08 | $16K | +4.9% | +2.7% | +17.3% |
| AKYA | SELL · 10b5-1 | 2024-06-06 | 2024-06-07 | $2.01 | $15K | +9.3% | +2.5% | +16.7% |
| AKYA | SELL · 10b5-1 | 2024-03-20 | 2024-03-22 | $4.97 | $37K | -11.2% | -17.9% | -53.1% |
| AKYA | SELL · 10b5-1 | 2024-03-13 | 2024-03-22 | $4.94 | $37K | -11.2% | -17.9% | -53.1% |
| AKYA | SELL · 10b5-1 | 2023-12-19 | 2023-12-20 | $4.48 | $34K | -7.5% | +5.6% | +4.8% |
| AKYA | SELL · 10b5-1 | 2023-12-12 | 2023-12-14 | $4.25 | $32K | +6.9% | -7.5% | +2.1% |
| AKYA | SELL · 10b5-1 | 2023-11-20 | 2023-11-22 | $4.39 | $33K | +9.5% | +17.4% | +34.4% |
| AKYA | SELL · 10b5-1 | 2023-06-06 | 2023-06-06 | $5.71 | $29K | +44.4% | +12.7% | -12.1% |
| AKYA | SELL · 10b5-1 | 2023-03-14 | 2023-03-16 | $9.18 | $46K | +1.5% | -6.3% | -4.4% |
| AKYA | SELL | 2022-12-06 | 2022-12-08 | $12.08 | $60K | -11.8% | -23.1% | -15.2% |
| AKYA | SELL | 2022-09-07 | 2022-09-09 | $12.83 | $64K | -15.2% | -15.0% | -8.8% |
| AKYA | SELL | 2022-06-15 | 2022-06-17 | $10.25 | $51K | +33.4% | +35.2% | +33.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.